Cargando…

Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire

BACKGROUND: The World Health Organization (WHO) recommends using insecticide-treated mosquito nets (ITNs) and intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) to prevent malaria in sub-Saharan Africa. Data on IPT-SP coverage and factors associated with placental malaria par...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanga-Bosson, Henriette A, Coffie, Patrick A, Kanhon, Serge, Sloan, Caroline, Kouakou, Firmin, Eholie, Serge P, Kone, Moussa, Dabis, François, Menan, Hervé, Ekouevi, Didier K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108318/
https://www.ncbi.nlm.nih.gov/pubmed/21529344
http://dx.doi.org/10.1186/1475-2875-10-105
_version_ 1782205305289965568
author Vanga-Bosson, Henriette A
Coffie, Patrick A
Kanhon, Serge
Sloan, Caroline
Kouakou, Firmin
Eholie, Serge P
Kone, Moussa
Dabis, François
Menan, Hervé
Ekouevi, Didier K
author_facet Vanga-Bosson, Henriette A
Coffie, Patrick A
Kanhon, Serge
Sloan, Caroline
Kouakou, Firmin
Eholie, Serge P
Kone, Moussa
Dabis, François
Menan, Hervé
Ekouevi, Didier K
author_sort Vanga-Bosson, Henriette A
collection PubMed
description BACKGROUND: The World Health Organization (WHO) recommends using insecticide-treated mosquito nets (ITNs) and intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) to prevent malaria in sub-Saharan Africa. Data on IPT-SP coverage and factors associated with placental malaria parasitaemia and low birth weight (LBW) are scarce in Côte d'Ivoire. METHODS: A multicentre, cross-sectional survey was conducted in Côte d'Ivoire from March to September 2008 at six urban and semi-urban antenatal clinics. Standardized forms were used to collect the demographic information and medical histories of women and their offspring. IPT-SP coverage (≥2 doses) as well as placental and congenital malaria prevalence parasitaemia were estimated. Regression logistics were used to study factors associated with placental malaria and LBW (birth weight of alive babies < 2,500 grams). RESULTS: Overall, 2,044 women with a median age of 24 years were included in this study. Among them 1017 (49.8%) received ≥2 doses of IPT-SP and 694 (34.0%) received one dose. A total of 99 mothers (4.8%) had placental malaria, and of them, four cases of congenital malaria were diagnosed. Factors that protected from maternal placental malaria parasitaemia were the use of one dose (adjusted odds ratio (aOR), 0.32; 95%CI: 0.19-0.55) or ≥2 doses IPT-SP (aOR: 0.18; 95%CI: 0.10-0.32); the use of ITNs (aOR: 0.47; 95%CI: 0.27-0.82). LBW was associated with primigravidity and placental malaria parasitaemia. CONCLUSION: IPT-SP decreases the rate of placental malaria parasitaemia and has a strong dose effect. Despite relatively successful IPT-SP coverage in Côte d'Ivoire, substantial commitments from national authorities are urgently required for such public health campaigns. Strategies, such as providing IPT-SP free of charge and directly observing treatment, should be implemented to increase the use of IPT-SP as well as other prophylactic methods.
format Online
Article
Text
id pubmed-3108318
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31083182011-06-07 Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire Vanga-Bosson, Henriette A Coffie, Patrick A Kanhon, Serge Sloan, Caroline Kouakou, Firmin Eholie, Serge P Kone, Moussa Dabis, François Menan, Hervé Ekouevi, Didier K Malar J Research BACKGROUND: The World Health Organization (WHO) recommends using insecticide-treated mosquito nets (ITNs) and intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) to prevent malaria in sub-Saharan Africa. Data on IPT-SP coverage and factors associated with placental malaria parasitaemia and low birth weight (LBW) are scarce in Côte d'Ivoire. METHODS: A multicentre, cross-sectional survey was conducted in Côte d'Ivoire from March to September 2008 at six urban and semi-urban antenatal clinics. Standardized forms were used to collect the demographic information and medical histories of women and their offspring. IPT-SP coverage (≥2 doses) as well as placental and congenital malaria prevalence parasitaemia were estimated. Regression logistics were used to study factors associated with placental malaria and LBW (birth weight of alive babies < 2,500 grams). RESULTS: Overall, 2,044 women with a median age of 24 years were included in this study. Among them 1017 (49.8%) received ≥2 doses of IPT-SP and 694 (34.0%) received one dose. A total of 99 mothers (4.8%) had placental malaria, and of them, four cases of congenital malaria were diagnosed. Factors that protected from maternal placental malaria parasitaemia were the use of one dose (adjusted odds ratio (aOR), 0.32; 95%CI: 0.19-0.55) or ≥2 doses IPT-SP (aOR: 0.18; 95%CI: 0.10-0.32); the use of ITNs (aOR: 0.47; 95%CI: 0.27-0.82). LBW was associated with primigravidity and placental malaria parasitaemia. CONCLUSION: IPT-SP decreases the rate of placental malaria parasitaemia and has a strong dose effect. Despite relatively successful IPT-SP coverage in Côte d'Ivoire, substantial commitments from national authorities are urgently required for such public health campaigns. Strategies, such as providing IPT-SP free of charge and directly observing treatment, should be implemented to increase the use of IPT-SP as well as other prophylactic methods. BioMed Central 2011-04-29 /pmc/articles/PMC3108318/ /pubmed/21529344 http://dx.doi.org/10.1186/1475-2875-10-105 Text en Copyright ©2011 Vanga-Bosson et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Vanga-Bosson, Henriette A
Coffie, Patrick A
Kanhon, Serge
Sloan, Caroline
Kouakou, Firmin
Eholie, Serge P
Kone, Moussa
Dabis, François
Menan, Hervé
Ekouevi, Didier K
Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire
title Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire
title_full Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire
title_fullStr Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire
title_full_unstemmed Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire
title_short Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire
title_sort coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in côte d'ivoire
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108318/
https://www.ncbi.nlm.nih.gov/pubmed/21529344
http://dx.doi.org/10.1186/1475-2875-10-105
work_keys_str_mv AT vangabossonhenriettea coverageofintermittentpreventiontreatmentwithsulphadoxinepyrimethamineamongpregnantwomenandcongenitalmalariaincotedivoire
AT coffiepatricka coverageofintermittentpreventiontreatmentwithsulphadoxinepyrimethamineamongpregnantwomenandcongenitalmalariaincotedivoire
AT kanhonserge coverageofintermittentpreventiontreatmentwithsulphadoxinepyrimethamineamongpregnantwomenandcongenitalmalariaincotedivoire
AT sloancaroline coverageofintermittentpreventiontreatmentwithsulphadoxinepyrimethamineamongpregnantwomenandcongenitalmalariaincotedivoire
AT kouakoufirmin coverageofintermittentpreventiontreatmentwithsulphadoxinepyrimethamineamongpregnantwomenandcongenitalmalariaincotedivoire
AT eholiesergep coverageofintermittentpreventiontreatmentwithsulphadoxinepyrimethamineamongpregnantwomenandcongenitalmalariaincotedivoire
AT konemoussa coverageofintermittentpreventiontreatmentwithsulphadoxinepyrimethamineamongpregnantwomenandcongenitalmalariaincotedivoire
AT dabisfrancois coverageofintermittentpreventiontreatmentwithsulphadoxinepyrimethamineamongpregnantwomenandcongenitalmalariaincotedivoire
AT menanherve coverageofintermittentpreventiontreatmentwithsulphadoxinepyrimethamineamongpregnantwomenandcongenitalmalariaincotedivoire
AT ekouevididierk coverageofintermittentpreventiontreatmentwithsulphadoxinepyrimethamineamongpregnantwomenandcongenitalmalariaincotedivoire